PTX-100のフェーズ2の検査で FDAの承認を得ています Prescient Therapeutics gains FDA approval for Phase 2 trials of its new cancer drug, PTX-100.

PTX-100の治療を目指すPTX-100の薬のフェーズ2の試験を開始 FDAの承認を受けています。 Prescient Therapeutics has received FDA approval to begin Phase 2 trials for its PTX-100 drug, which aims to treat advanced solid tumors. この承認はフェーズ1の試験に成功し,薬の開発における著しい進歩を表明する. This approval follows successful Phase 1 trials and marks a significant advancement in the drug's development. PTX-100は、他のがん療法と併せて安全性、寛容性、有効性を検証する新作PI3K/MTER抑制剤である. PTX-100 is a novel dual PI3K/mTOR inhibitor that will be tested for safety, tolerability, and effectiveness in combination with other cancer therapies.